UBS lowered the firm’s price target on Illumina to $111 from $122 and keeps a Neutral rating on the shares. UBS believes Street estimates are too high, though has a positive view of Illumina’s market leadership position in nextgen sequencing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ILMN: